The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.
The SfPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients and the treatments best suited for their cancer. This is possible through research, communication, and collaboration amongst our members and with outreach to the cancer therapy community as a whole. To further the mission, we offer our members the following exclusive benefits
- SfPM members in good standing (dues paid through Dec. 31, ) are eligible for self nominations in our monthly seminars
- Exclusive access to our biannual newsletter curated by our board with articles, news and insights about the world of functional precision medicine.
- A members exclusive directory with information on research interests and home institutions to facilitate collaboration and networking
- Facilitate trainee placements in post-doc and industry settings by recognizing shared interests and partnerships
- Free registration for SfPM Annual Meetings and special conferences
- Access to recordings of our virtual meetings along with contact information of speakers to connect with
- Many more ongoing benefits
Applications for membership may be submitted at any time during the year. We look forward to having you onboard!
Virtual Monthly Seminars
Come join us for our Virtual Monthly Seminar which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series is must attend for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.
Sara Cherry, PhD
University of Pennsylvania
NOVEMBER 1, 2021
Clinical Utility of Functional Precision Medicine in the Management of Recurrent/Relapsed Childhood Rhabdomyosarcoma
The Azzam Lab at Florida International University collaborates with clinicians at Nicklaus Children’s Hospital to guide therapeutic decisions for a 7-year old patient with metastatic refractory rhabdomyosarcoma using a personalized functional precision oncology approach. Their guided treatment plan led to longer progression-free survival than the regimen on which the patient had just experienced progression. This report is the first demonstration of the efficacy of functional precision medicine in guiding treatments in children.
OCTOBER 6, 2021
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models
Researchers at MIT and Dana-Farber Cancer Institute have developed a high-throughput assay that detects subtle changes in the mass of individual drug-treated cancer cells as a surrogate biomarker for patient treatment response. Their findings suggest cell mass is a promising functional biomarker for cancers and drugs that lack genomic biomarkers.
OCTOBER 3, 2021
Precision Oncology: Beyond Biomarkers
We would like to invite you to a webinar co-hosted by Oncology Convention Expo, Precision Oncology: Beyond Biomarkers on 5th October at 14:00 (BST).
JUNE 23, 2021
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening
Sanford M. Simon and his group tested over 5,000 compounds, either already approved for other clinical uses or in clinical trials, to see whether any of the compounds could be repurposed to treat fibrolamellar. The team used PDX models to uncover a few classes of therapeutics that eliminate fibrolamellar tumor cells grown in mice.
JUNE 16, 2021
2021 VIRTUAL Functional Precision Medicine in Blood Cancer
The 2021 Functional Precision Medicine in Blood Cancer Symposium which took place virtually on March 25-26th, 2021 was very interesting and well attended. If you were not able to make it please take a moment to watch the recording by clicking on the "Learn More" button below.